Bank of America Forecasts Strong Price Appreciation for Metsera (NASDAQ:MTSR) Stock

Key Points

• Bank of America has raised its target price for Metsera (NASDAQ:MTSR) from $45.00 to $50.00, suggesting a potential upside of 38.66% based on the current stock price, while maintaining a "buy" rating.
• Other brokerages like Wells Fargo and Guggenheim have also issued positive ratings and target prices for the stock, with a consensus rating of "Buy" and an average target price of $59.00.
• In the first quarter, significant institutional investments were made in Metsera, including new positions from companies such as Alphabet Inc. and T. Rowe Price, demonstrating strong interest in the company.

Metsera (NASDAQ:MTSR - Get Free Report) had its target price upped by investment analysts at Bank of America from $45.00 to $50.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Bank of America's target price would indicate a potential upside of 38.66% from the company's current price.

Several other brokerages have also recently commented on MTSR. Wells Fargo & Company began coverage on Metsera in a report on Friday, June 20th. They issued an "overweight" rating and a $65.00 target price on the stock. Guggenheim increased their price target on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $59.00.

Metsera Stock Up 3.0%

NASDAQ MTSR traded up $1.04 during trading on Thursday, hitting $36.06. 700,825 shares of the company's stock were exchanged, compared to its average volume of 1,001,911. Metsera has a fifty-two week low of $12.30 and a fifty-two week high of $47.40. The stock's 50 day moving average price is $33.73 and its two-hundred day moving average price is $28.44.

Metsera (NASDAQ:MTSR - Get Free Report) last issued its earnings results on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MTSR. Alphabet Inc. bought a new position in Metsera in the 1st quarter worth about $135,059,000. T. Rowe Price Investment Management Inc. bought a new position in Metsera in the 1st quarter worth about $78,748,000. Jennison Associates LLC bought a new position in Metsera in the 1st quarter worth about $9,679,000. TD Asset Management Inc bought a new position in Metsera in the 1st quarter worth about $2,091,000. Finally, Wellington Management Group LLP bought a new stake in shares of Metsera during the 1st quarter valued at about $65,382,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.